KPT-IST-391

A Phase I Trial of Selinexor, Ruxolitinib and Methylprednisolone for Patients With Relapsed/Refractory Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
30 patients (estimated)
Sponsors
Oncotherapeutics
Tags
Exportin-1 (XPO1) Inhibitor, Selective Inhibiton of Nuclear Export (SINE)
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
2041
NCT Identifier
NCT06225310

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.